{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:00:51Z","timestamp":1780380051275,"version":"3.54.1"},"reference-count":10,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Nodular lymphocyte\u2013predominant Hodgkin lymphoma (NLPHL) accounts for \u223c 5% of Hodgkin lymphoma cases. The disease is characterized by a strong CD20 expression on the malignant cells and a more indolent clinical course compared with classic HL. Anti-CD20 antibody treatment has shown clinical activity in relapsed NLPHL. In this phase 2 trial, we investigated rituximab in newly diagnosed stage IA NLPHL patients. Four weekly applications at 375 mg\/m2 were given. Among the 28 evaluable patients, overall response rate was 100%, 24 patients (85.7%) achieved complete remission, and 4 (14.3%) achieved partial remission. At a median follow-up of 43 months, overall survival was 100%; progression-free survival at 12, 24, and 36 months was 96.4%, 85.3%, and 81.4%, respectively. No grade 3 or 4 toxicity was observed. Although treatment results with rituximab appear inferior compared with radiotherapy and combined-modality approaches in early-stage patients, investigation of anti-CD20 antibody-based combinations in NLPHL is warranted. This study was registered at www.clinicaltrials.gov as #NCT00346684.<\/jats:p>","DOI":"10.1182\/blood-2011-06-361055","type":"journal-article","created":{"date-parts":[[2011,8,10]],"date-time":"2011-08-10T02:19:18Z","timestamp":1312942758000},"page":"4363-4365","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":103,"title":["Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group"],"prefix":"10.1182","volume":"118","author":[{"given":"Dennis A.","family":"Eichenauer","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine and"},{"name":"German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fuchs","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine and"},{"name":"German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Pluetschow","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine and"},{"name":"German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Klimm","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine and"},{"name":"German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Halbsguth","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine and"},{"name":"German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"B\u00f6ll","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine and"},{"name":"German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine and"},{"name":"German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Nogov\u00e1","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine and"},{"name":"German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine and"},{"name":"German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111807520318000_B1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/annonc\/mdq181","article-title":"Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"21","author":"Engert","year":"2010","journal-title":"Ann Oncol"},{"issue":"3","key":"2019111807520318000_B2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.","volume":"26","author":"Nogova","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111807520318000_B3","first-page":"1889","article-title":"European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.","volume":"96","author":"Anagnostopoulos","year":"2000","journal-title":"Blood"},{"issue":"1","key":"2019111807520318000_B4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","article-title":"Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).","volume":"111","author":"Schulz","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111807520318000_B5","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.","volume":"101","author":"Ekstrand","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2019111807520318000_B6","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.","volume":"17","author":"Diehl","year":"1999","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111807520318000_B7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/cncr.22762","article-title":"Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma: experience from the European Network Group on Pediatric Hodgkin Lymphoma.","volume":"110","author":"Mauz-Korholz","year":"2007","journal-title":"Cancer"},{"issue":"5","key":"2019111807520318000_B8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma.","volume":"28","author":"Al-Mansour","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111807520318000_B9","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/annonc\/mdi323","article-title":"Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).","volume":"16","author":"Nogova","year":"2005","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111807520318000_B10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.","volume":"28","author":"Chen","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/16\/4363\/1342700\/zh804211004363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/16\/4363\/1342700\/zh804211004363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:06:00Z","timestamp":1574082360000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/16\/4363\/28848\/Phase-2-study-of-rituximab-in-newly-diagnosed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,20]]},"references-count":10,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2011,10,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-06-361055","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,20]]}}}